Efficacité spectaculaire d'une chimiothérapie par 5-fluoro-uracile et dacarbazine chez un malade atteint de glucagonome métastatique avec insuffisance cardiaque

Gastroenterologie Clinique et Biologique

Volumn 34, Issue 1, 2010, Pages 106-110

  de Mestier, L ^a   Hammel, P ^a   Hentic, O ^a   Dove, P ^b   Levy P ^a   Ruszniewski, P ^a  

^a BEAUJON HOSPITAL   (France)

^b Centre Médical de Bligny   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; FLUOROURACIL; OCTREOTIDE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; ERYTHEMA; GLUCAGONOMA; HEART FAILURE; HUMAN; LIVER METASTASIS; METASTASIS; PANCREAS SURGERY; SYMPTOM; ADULT; FEMALE; LIVER TUMOR; PANCREAS TUMOR; PATHOLOGY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOMYOPATHY, DILATED; DACARBAZINE; FEMALE; FLUOROURACIL; GLUCAGONOMA; HUMANS; LIVER NEOPLASMS; PANCREATIC NEOPLASMS;

EID: 74349115433     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.07.037     Document Type: Article

References (24)

1. Lévy P., Ruszniewski P., and Sauvanet A. Traité de pancréatologie clinique (2005), Médecine-Sciences Flammarion 283-339
2. SNFGE. Thésaurus national de cancérologie digestive. 2007. http://www.snfge.org/01-Bibliotheque/0G-Thesaurus-cancerologie (site consulté en février 2009).
3. Moertel C.G., Lefkopoulo M., Lipsitz S., Hahn R.G., and Klaassen D. Streptozocin-doxorubicin, streptozocin-fluoro-uracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (1992) 519-523
4. Kianmanesh R., Sauvanet A., Hentic O., Couvelard A., Lévy P., Vilgrain V., et al. Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg 247 (2008) 659-665
5. Chang-Chretien K., Chew J.T., and Judge D.P. Reversible dilated cardiomyopathy associated with glucagonoma. Heart 90 (2004) e44
6. Takemiya M., Miyayama H., Takeya M., Takeuchi T., Konno T., Kitoh M., et al. A postmortem study of malignant glucagonoma with heart muscle hypertrophy, including chemical, histochemical, immunohistological and ultrastructural observations. Hum Pathol 12 (1981) 988-999
7. Guillausseau P.J., Guillausseau C., Villet R., Kaloustian E., Valleur P., Hautefeuille P., et al. Glucagonomas. Clinical, biological, anatomopathological and therapeutic aspects (general review of 130 cases). Gastroenterol Clin Biol 6 (1982) 1029-1041
8. Jensen R.T., and Gardner J.D. The pancreas biology, pathobiology and disease. 2nd ed. (1993), Raven Press, New York pp. 931-78
9. Bouin M., and Aoust L.D. Réponse clinique d'un glucagonome atypique à un traitement par analogue à la somatostatine. Gastroenterol Clin Biol 26 (2002) 926-929
10. Bonaventure C., Merle P., Grezard P., Ruiz J.M., Chevallier M., Scoazec J.Y., et al. Glucagonome révélé par un érythème nécrolytique migrateur. Gastroenterol Clin Biol 27 (2003) 230-232
11. Chu Q.D., Al Kasspooles M.F., Smith J.L., Nava H.R., Douglass Jr. H.O., Driscoll D., et al. Is glucagonoma of the pancreas a curable disease?. Int J Pancreatol 29 (2001) 155-162
12. Kianmanesh R., O'Toole D., Sauvanet A., Ruszniewski P., and Belghiti J. Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors. J Chir (Paris) 142 (2005) 132-149
13. Madeira I., Terris B., Voss M., Denys A., Sauvanet A., Fléjou J.F., et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 43 (1998) 422-427
14. Clarke N., and Kabadi U. Glucagonoma syndrome. Encyclopedia of hormones (2003) 62-65
15. Frankton S., and Bloom S.R. Gastrointestinal endocrine tumours. Glucagonomas. Baillieres Clin Gastroenterol 10 (1996) 697-705
16. Dominguez S., Denys A., Madeira I., Hammel P., Vilgrain V., Menu Y., et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol 12 (2000) 151-157
17. Tomassetti P., Migliori M., Corinaldesi R., and Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 14 (2000) 557-560
18. Kurose T., Seino Y., Ishida H., Fujita J., Taminato T., Matsukura M., et al. Successful treatment of metastatic glucagonoma with dacarbazine. Lancet 1 (1984) 621-622
19. van der Loos T.L., Lambrecht E.R., and Lambers J.C. Successful treatment of glucagonoma-related necrolytic migratory erythema with dacarbazine. J Am Acad Dermatol 16 (1987) 468-472
20. Jeanmougin M., Civatte J., Bonvalet D., Passa P., Verola O., and Zylberait D. Metastatic glucagonoma. Complete remission by dacarbazine (5 years' recession). Ann Dermatol Venereol 115 (1988) 833-838
21. Altimari A.F., Badrinath K., Reisel H.J., and Prinz R.A. DTIC therapy in patients with malignant intra-abdominal neuroendocrine tumors. Surgery 102 (1987) 1009-1017
22. Bajetta E., Ferrari L., Procopio G., Catena L., Ferrario E., Martinetti A., et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 13 (2002) 614-621
23. Strohm W.D. Paraneoplastic spastic tetraparesis in glucagonoma syndrome. Successful therapy with octreotide, dacarbazine and interferon-alpha. Z Gastroenterol 34 (1996) 438-445
24. O'Toole D., Salazar R., Falconi M., Kaltsas G., Couvelard A., de Herder W.W., et al. Rare functioning pancreatic endocrine tumors. Neuroendocrinology 84 (2006) 189-195